Figure 3.
Figure 3. Distribution of levels of VWF:RCo and FVIII:C activities in the entire cohort of 796 patients included in RENAWI-2.31 Patients with VWD1, VWD2A, VWD2B, VWD2M, or VWD3 (from left to right) are distributed within 3 different groups from the bottom to the top according to their baseline levels of VWF:RCo and FVIII:C. Severe cases (pink area) are characterized by the lowest levels of activities (VWF:RCo <10 and FVIII:C <20 IU/dL); moderate cases (light blue) by the moderately reduced levels of activities (VWF:RCo = 10-30 and FVIII:C = 20-40 IU/dL); mild cases (yellow) by the less reduced levels of activities (VWF:RCo = 31-55 and FVIII:C >40 IU/dL). Note the extreme heterogeneity within VWD1, VWD2A, VWD2B, and VWD2M. More detailed information is provided in Federici et al.31

Distribution of levels of VWF:RCo and FVIII:C activities in the entire cohort of 796 patients included in RENAWI-2.31  Patients with VWD1, VWD2A, VWD2B, VWD2M, or VWD3 (from left to right) are distributed within 3 different groups from the bottom to the top according to their baseline levels of VWF:RCo and FVIII:C. Severe cases (pink area) are characterized by the lowest levels of activities (VWF:RCo <10 and FVIII:C <20 IU/dL); moderate cases (light blue) by the moderately reduced levels of activities (VWF:RCo = 10-30 and FVIII:C = 20-40 IU/dL); mild cases (yellow) by the less reduced levels of activities (VWF:RCo = 31-55 and FVIII:C >40 IU/dL). Note the extreme heterogeneity within VWD1, VWD2A, VWD2B, and VWD2M. More detailed information is provided in Federici et al.31 

Close Modal

or Create an Account

Close Modal
Close Modal